SG11202101173TA - Ox40-binding polypeptides and uses thereof - Google Patents

Ox40-binding polypeptides and uses thereof

Info

Publication number
SG11202101173TA
SG11202101173TA SG11202101173TA SG11202101173TA SG11202101173TA SG 11202101173T A SG11202101173T A SG 11202101173TA SG 11202101173T A SG11202101173T A SG 11202101173TA SG 11202101173T A SG11202101173T A SG 11202101173TA SG 11202101173T A SG11202101173T A SG 11202101173TA
Authority
SG
Singapore
Prior art keywords
binding polypeptides
polypeptides
binding
Prior art date
Application number
SG11202101173TA
Other languages
English (en)
Inventor
John C Timmer
William Crago
Kyle Jones
Florian Sulzmaier
Bryan Becklund
Brendan P Eckelman
Katelyn Willis
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of SG11202101173TA publication Critical patent/SG11202101173TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202101173TA 2018-08-13 2019-08-12 Ox40-binding polypeptides and uses thereof SG11202101173TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862718106P 2018-08-13 2018-08-13
PCT/US2019/046156 WO2020036867A1 (en) 2018-08-13 2019-08-12 Ox40-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
SG11202101173TA true SG11202101173TA (en) 2021-03-30

Family

ID=67841151

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101173TA SG11202101173TA (en) 2018-08-13 2019-08-12 Ox40-binding polypeptides and uses thereof

Country Status (16)

Country Link
US (2) US11447556B2 (he)
EP (1) EP3837285A1 (he)
JP (2) JP7462611B2 (he)
KR (1) KR20210044243A (he)
CN (1) CN112601761A (he)
AR (1) AR114552A1 (he)
AU (1) AU2019321490A1 (he)
BR (1) BR112021002164A2 (he)
CA (1) CA3107767A1 (he)
CL (1) CL2021000347A1 (he)
IL (1) IL280808A (he)
MX (1) MX2021001703A (he)
PH (1) PH12021550289A1 (he)
SG (1) SG11202101173TA (he)
TW (1) TW202019968A (he)
WO (1) WO2020036867A1 (he)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI802923B (zh) * 2020-06-30 2023-05-21 大陸商和鉑醫藥（上海）有限責任公司 標靶ｏｘ４０的抗體及其製備方法和應用
TWI835166B (zh) * 2021-06-17 2024-03-11 大陸商和鉑醫藥（上海）有限責任公司 靶向pd-1和/或ox40的特異性結合蛋白及其應用
CN118574849A (zh) * 2021-12-17 2024-08-30 上海复宏汉霖生物技术股份有限公司 抗ox40抗体和使用方法
WO2023109900A1 (en) * 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
GB202210969D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Activation induced marker assay

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US8268582B2 (en) 2003-10-22 2012-09-18 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
DK2650020T3 (en) 2005-05-06 2017-01-16 Providence Health & Services - Oregon Trimeric OX40 immunoglobulin fusion protein and methods for applications.
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
WO2007132461A2 (en) 2006-05-11 2007-11-22 Ramot At Tel Aviv University Ltd. Classification of protein sequences and uses of classified proteins
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
HUE042114T2 (hu) 2009-02-17 2019-06-28 Ucb Biopharma Sprl Humán OX40-re specifikus ellenanyag-molekulák
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
EP2523686A2 (en) * 2010-01-14 2012-11-21 Glaxo Group Limited Liver targeting domain antibodies
US10706955B2 (en) 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
ES2537207T3 (es) 2010-08-16 2015-06-03 Novimmune S.A. Métodos para la generación de anticuerpos multiespecíficos y multivalentes
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
IL311502A (he) 2012-02-27 2024-05-01 Ablynx Nv פוליפפטידים קושרי cx3cr1
JP6391564B2 (ja) 2012-04-30 2018-09-19 メディミューン，エルエルシー 低減されたエフェクター機能及び延長された半減期を有する分子、組成物、並びにそれらの使用
CA2879814A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US10533054B2 (en) * 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
MX2015012059A (es) 2013-03-15 2016-01-12 Merck Patent Gmbh Anticuerpos biespecificos tetravalentes.
MX2015013288A (es) 2013-03-18 2016-04-07 Biocerox Prod Bv Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos.
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP3083687A2 (en) 2013-12-17 2016-10-26 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SG11201703605QA (en) 2014-11-17 2017-06-29 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CA2974192C (en) 2015-01-21 2024-02-20 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
EP3268392A2 (en) 2015-03-13 2018-01-17 CytomX Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN108026158A (zh) * 2015-08-12 2018-05-11 免疫医疗有限公司 Gitrl融合蛋白及其用途
SG11201805422WA (en) * 2016-01-11 2018-07-30 Inhibrx Inc Multivalent and multispecific ox40-binding fusion proteins
AU2017384528A1 (en) 2016-12-19 2019-07-04 Ichnos Sciences SA Novel TNFR agonists and uses thereof

Also Published As

Publication number Publication date
BR112021002164A2 (pt) 2021-08-03
PH12021550289A1 (en) 2021-10-25
US20200055946A1 (en) 2020-02-20
KR20210044243A (ko) 2021-04-22
CN112601761A (zh) 2021-04-02
US20230128188A1 (en) 2023-04-27
WO2020036867A1 (en) 2020-02-20
TW202019968A (zh) 2020-06-01
AU2019321490A1 (en) 2021-02-18
JP7462611B2 (ja) 2024-04-05
CA3107767A1 (en) 2020-02-20
MX2021001703A (es) 2021-04-19
US12012459B2 (en) 2024-06-18
JP2021533761A (ja) 2021-12-09
IL280808A (he) 2021-04-29
AU2019321490A8 (en) 2021-03-25
EP3837285A1 (en) 2021-06-23
JP2024075739A (ja) 2024-06-04
US11447556B2 (en) 2022-09-20
CL2021000347A1 (es) 2021-09-03
AR114552A1 (es) 2020-09-16

Similar Documents

Publication Publication Date Title
IL273327A (he) פוליפפטידים כימרים ושימושים שלהם
EP3704219C0 (en) POLYPEPTIDES AND COMPOSITIONS CONTAINING SUCH POLYPEPTIDES
IL279458A (he) ניאו-אנטיגנים ושימושים שלהם
IL287781A (he) פוליפפטידים נקשרי-12a clec ושימושים בהם
IL268593A (he) וריאנטים של פוליפפטיד ושימושים בהם
EP3405222C0 (en) NEW POLYPEPTIDES AND THEIR MEDICAL USES
IL280808A (he) פוליפפטידים נקשרי- ox40ושימושים בהם
IL287782A (he) פוליפפטידים נקשרי-33cd ושימושים בהם
EP3813861A4 (en) HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES
EP3728294A4 (en) Insecticidal polypeptides and uses thereof
GB201819200D0 (en) Polypeptide and uses thereof
SG11202006669RA (en) Peptides and uses thereof
IL282547A (he) חלבוני דסטורפין ממוזערים והשימוש בהם
GB201707139D0 (en) Polypeptides
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
IL281762A (he) חלבוני ארגינאז1
EP3630795C0 (en) MANIPULATED ALDOLASE POLYPEPTIDES AND USES THEREOF
EP3480212C0 (en) IL13RALPHA2 PEPTIDE AND ITS USES
EP3684796A4 (en) SUCCINATE REGULATORY POLYPEPTIDES AND USES
SG11202007112SA (en) Emm-37 materials and processes and uses thereof
GB201803363D0 (en) New materials and uses thereof
EP3611181A4 (en) ATP1A1T TARGETING POLYPEPTIDE AND USES
IL280369A (he) מיוקינזים ושימושים שלהם
GB201812328D0 (en) Polypeptides and uses thereof
HUP1700012A2 (en) Novel proteins and use thereof